{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:07:52Z","timestamp":1791994072514,"version":"4.4.0"},"reference-count":71,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.ejmech.2013.11.026","type":"journal-article","created":{"date-parts":[[2013,12,7]],"date-time":"2013-12-07T16:00:59Z","timestamp":1386432059000},"page":"56-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease"],"prefix":"10.1016","volume":"73","author":[{"given":"Pedro","family":"Gonz\u00e1lez-Naranjo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"P\u00e9rez-Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria E.","family":"Campillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente J.","family":"Ar\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Gir\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"S\u00e1nchez-Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"G\u00f3mez-Ca\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s","family":"Garc\u00eda-Arencibia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A.","family":"P\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2013.11.026_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/gerona\/61.3.267","article-title":"Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis","volume":"61","author":"Claassen","year":"2006","journal-title":"J.\u00a0Gerontol. A Biol. Sci. Med. Sci."},{"key":"10.1016\/j.ejmech.2013.11.026_bib2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/01.wco.0000247605.57567.9a","article-title":"Treatment of attention deficits in neurological disorders","volume":"19","author":"Coulthard","year":"2006","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ejmech.2013.11.026_bib3","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1517\/13543784.16.12.1987","article-title":"An update on the pharmacology of galantamine","volume":"16","author":"Villarroya","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejmech.2013.11.026_bib4","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1093\/brain\/awl280","article-title":"Therapeutic approaches to Alzheimer's disease","volume":"129","author":"Klafki","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2013.11.026_bib5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00702-008-0022-y","article-title":"Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis","volume":"115","author":"Kamal","year":"2008","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.ejmech.2013.11.026_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1017\/S1461145705005833","article-title":"Targeting acetylcholinesterase and butyrylcholinesterase in dementia","volume":"9","author":"Lane","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejmech.2013.11.026_bib7","first-page":"1113","article-title":"Rivastigmine in Alzheimer's disease: cognitive function and quality of life","volume":"3","author":"Annicchiarico","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ejmech.2013.11.026_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/156720507781077313","article-title":"Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase","volume":"4","author":"Bullock","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejmech.2013.11.026_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1389557013406864","article-title":"Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease","volume":"1","author":"Castro","year":"2001","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib10","doi-asserted-by":"crossref","first-page":"10447","DOI":"10.1021\/bi0101392","article-title":"A\u00a0structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation","volume":"40","author":"De Ferrari","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2013.11.026_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/1567205054367928","article-title":"Acetylcholinesterase-amyloid-beta-peptide interaction: effect of Congo Red and the role of the Wnt pathway","volume":"2","author":"Inestrosa","year":"2005","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejmech.2013.11.026_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1432-1033.1996.00036.x","article-title":"Asp7O in the peripheral anionic site of human butyrylcholinesterase","volume":"235","author":"Masson","year":"1996","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0167-4838(99)00115-6","article-title":"Interaction between the peripheral site residues of human butyrylcholinesterase, D70 and Y332, in binding and hydrolysis of substrates","volume":"1433","author":"Masson","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2013.11.026_bib14","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.0602922103","article-title":"Butyrylcholinesterase attenuates amyloid fibril formation in\u00a0vitro","volume":"103","author":"Diamant","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2013.11.026_bib15","doi-asserted-by":"crossref","first-page":"17213","DOI":"10.1073\/pnas.0508575102","article-title":"Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent","volume":"102","author":"Greig","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2013.11.026_bib16","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.2174\/092986711797535245","article-title":"Multi-target-directed ligands in Alzheimer's disease treatment","volume":"18","author":"Bajda","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib17","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1021\/jm1000024","article-title":"Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents","volume":"53","author":"Rook","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/cmdc.201000008","article-title":"Dual-acting drugs: an in\u00a0vitro study of nonimidazole histamine H3 receptor antagonists combining anticholinesterase activity","volume":"5","author":"Incerti","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2013.11.026_bib19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bmcl.2007.09.100","article-title":"Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds","volume":"18","author":"Piazzi","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2013.11.026_bib20","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1016\/j.bmc.2010.06.042","article-title":"Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer's disease","volume":"18","author":"Huang","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib21","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1021\/jm1003073","article-title":"Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity","volume":"53","author":"Hieke","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib22","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1021\/jm901614b","article-title":"Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism","volume":"53","author":"Lange","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2174\/138955709788167628","article-title":"Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease","volume":"9","author":"Campillo","year":"2009","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib24","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.3390\/ph3082689","article-title":"Cannabinoids and dementia: review of clinical and preclinical data","volume":"3","author":"Walter","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2013.11.026_bib25","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation","volume":"25","author":"Ramirez","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2013.11.026_bib26","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.neuint.2010.10.010","article-title":"Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex","volume":"57","author":"Lee","year":"2010","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2013.11.026_bib27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.brainres.2010.12.061","article-title":"Distribution patterns of cannabinoid CB1 receptors in the hippocampus of APPswe\/PS1DeltaE9 double transgenic mice","volume":"376","author":"Kalifa","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2013.11.026_bib28","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1523\/JNEUROSCI.3923-04.2005","article-title":"A\u00a0glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis","volume":"25","author":"Benito","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2013.11.026_bib29","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","article-title":"Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains","volume":"23","author":"Benito","year":"2003","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2013.11.026_bib30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bjp.0707505","article-title":"Cannabinoid CB2 receptors in human brain inflammation","volume":"153","author":"Benito","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2013.11.026_bib31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.brainres.2009.05.098","article-title":"The activation of cannabinoid CB2 receptors stimulates in situ and in\u00a0vitro beta-amyloid removal by human macrophages","volume":"1283","author":"Tolon","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2013.11.026_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/157015907780866884","article-title":"The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration","volume":"5","author":"Ashton","year":"2007","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejmech.2013.11.026_bib33","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.neurobiolaging.2007.04.028","article-title":"Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats","volume":"29","author":"Marchalant","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejmech.2013.11.026_bib34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/sj.bjp.0707446","article-title":"Alzheimer's disease; taking the edge off with cannabinoids?","volume":"152","author":"Campbell","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2013.11.026_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/0-387-23226-5_20","article-title":"Phosphorylated amyloid-beta: the toxic intermediate in alzheimer's disease neurodegeneration","volume":"38","author":"Milton","year":"2005","journal-title":"Subcell. Biochem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1742-2094-2-29","article-title":"Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation","volume":"2","author":"Ehrhart","year":"2005","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ejmech.2013.11.026_bib37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/1567205011310030002","article-title":"Multitarget cannabinoids as novel strategy for Alzheimer disease","volume":"10","author":"Gonzalez-Naranjo","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejmech.2013.11.026_bib38","unstructured":"J.A. P\u00e1ez, N.E. Campillo, P. Gonz\u00e1lez-Naranjo, C. P\u00e9rez, V.J. Ar\u00e1n, M.I. Martin Fontelles, R. Gir\u00f3n, E.M. S\u00e1nchez, Preparation of 3-Indazolyl Ethers with Cannabinoid and\/or Cholinergic Properties Useful for Treating Various Diseases, Universidad Rey Juan Carlos, Spain, ES 2378139 (Oct. 1, 2009), WO 2011039388 (Sep 30, 2010)."},{"key":"10.1016\/j.ejmech.2013.11.026_bib39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ejmech.2012.10.045","article-title":"2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents","volume":"58","author":"Rizzo","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejmech.2004.10.002","article-title":"Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study","volume":"40","author":"Montero","year":"2005","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib41","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/cber.19420750911","article-title":"Representation of o-hydrazino-benzoic acids and indazolones by reduction of diazotated anthranilic acids with sulphuric acid","volume":"75","author":"Pfannstiel","year":"1942","journal-title":"Chem. Ber."},{"key":"10.1016\/j.ejmech.2013.11.026_bib42","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/jlac.199619960507","article-title":"Analogues of cytostatic, fused indazolinones: synthesis, conformational analysis and cytostatic activity against HeLa cells of some 1-substituted indazolols, 2-substituted indazolinones, and related compounds","author":"Ar\u00e1n","year":"1996","journal-title":"Liebigs Ann."},{"key":"10.1016\/j.ejmech.2013.11.026_bib43","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-1978-24840","article-title":"Synthesis, properties and reactions of 1H-indazol-3-ols and 1-2-dihydro-3h-indazol-3-ones","author":"Baiocchi","year":"1978","journal-title":"Synthesis-Stuttgart"},{"key":"10.1016\/j.ejmech.2013.11.026_bib44","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1021\/jm00107a023","article-title":"Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity","volume":"34","author":"Bruneau","year":"1991","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejmech.2012.10.009","article-title":"Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug","volume":"58","author":"Vega","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0926-860X(98)00110-0","article-title":"Reduction of aromatic nitro compounds with hydrazine hydrate in the presence of an iron oxide hydroxide catalyst. I. The reduction of monosubstituted nitrobenzenes with hydrazine hydrate in the presence of ferrihydrite","volume":"172","author":"Lauwiner","year":"1998","journal-title":"Appl. Catal. A Gen."},{"key":"10.1016\/j.ejmech.2013.11.026_bib47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A\u00a0new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2013.11.026_bib48","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1021\/jm049782n","article-title":"Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues","volume":"47","author":"Bolognesi","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib49","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1023\/A:1022869222652","article-title":"Cholinesterases: new roles in brain function and in Alzheimer's disease","volume":"28","author":"Giacobini","year":"2003","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejmech.2013.11.026_bib50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cbi.2007.09.006","article-title":"alpha,beta-Dehydrophenylalanine choline esters, a new class of reversible inhibitors of human acetylcholinesterase and butyrylcholinesterase","volume":"171","author":"Grigoryan","year":"2008","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2013.11.026_bib51","series-title":"GraphPad_Prism","year":"2013"},{"key":"10.1016\/j.ejmech.2013.11.026_bib52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0006-2952(02)01514-9","article-title":"beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies","volume":"65","author":"Bartolini","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2013.11.026_bib53","doi-asserted-by":"crossref","first-page":"7480","DOI":"10.1016\/j.bmc.2007.07.056","article-title":"Discovery of 1,1-dioxo-1,2,6-thiadiazine-5-carboxamide derivatives as cannabinoid-like molecules with agonist and antagonist activity","volume":"15","author":"Cano","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib54","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/cmdc.201100568","article-title":"Chromenopyrazoles: non-psychoactive and selective CB(1) cannabinoid agonists with peripheral antinociceptive properties","volume":"7","author":"Cumella","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2013.11.026_bib55","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1476-5381.1992.tb09088.x","article-title":"Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine","volume":"105","author":"Pertwee","year":"1992","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2013.11.026_bib56","first-page":"191","article-title":"The bioassay of cannabinoids using the mouse isolated vas deferens","volume":"123","author":"Thomas","year":"2006","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.ejmech.2013.11.026_bib57","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1021\/jf010586o","article-title":"Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe","volume":"49","author":"Ou","year":"2001","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib58","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1021\/jf0305231","article-title":"Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay","volume":"52","author":"Davalos","year":"2004","journal-title":"J.\u00a0Agric. Food. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib59","unstructured":"SYBYL 7.2, Tripos International, 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA."},{"key":"10.1016\/j.ejmech.2013.11.026_bib60","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1039\/C0CP01456G","article-title":"Dissimilar interaction of CB1\/CB2 with lipid bilayers as revealed by molecular dynamics simulation","volume":"13","author":"Ramos","year":"2011","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.ejmech.2013.11.026_bib61","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.289.5480.739","article-title":"Crystal structure of rhodopsin: a G protein-coupled receptor","volume":"289","author":"Palczewski","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2013.11.026_bib62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.bjp.0707567","article-title":"Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands","volume":"153","author":"Poso","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2013.11.026_bib63","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1107\/S0907444900010659","article-title":"Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II","volume":"56","author":"Kryger","year":"2000","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2013.11.026_bib64","doi-asserted-by":"crossref","first-page":"41141","DOI":"10.1074\/jbc.M210241200","article-title":"Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products","volume":"278","author":"Nicolet","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib65","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1110\/ps.9.2.252","article-title":"Structure-based thermodynamic analysis of the dissociation of protein phosphatase-1 catalytic subunit and microcystin-LR docked complexes","volume":"9","author":"Lavigne","year":"2000","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2013.11.026_bib66","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2013.11.026_bib67","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0022-3565(24)35367-4","article-title":"Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor","volume":"292","author":"Griffin","year":"2000","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2013.11.026_bib68","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1476-5381.1975.tb07373.x","article-title":"Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antogonist potencies of narcotic analgesics","volume":"53","author":"Hughes","year":"1975","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2013.11.026_bib69","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/(SICI)1096-987X(199604)17:5\/6<490::AID-JCC1>3.0.CO;2-P","article-title":"Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94","volume":"17","author":"Halgren","year":"1996","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib70","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/(SICI)1096-987X(199604)17:5\/6<520::AID-JCC2>3.0.CO;2-W","article-title":"Merck molecular force field. 2. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions","volume":"17","author":"Halgren","year":"1996","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2013.11.026_bib71","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/bioinformatics\/15.4.327","article-title":"Automated analysis\u00a0of interatomic contacts in proteins","volume":"15","author":"Sobolev","year":"1999","journal-title":"Bioinformatics"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352341300768X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352341300768X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T03:15:37Z","timestamp":1746069337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352341300768X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":71,"alternative-id":["S022352341300768X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2013.11.026","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2013.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}